Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 5, 2012, Pages 462-472

  Khitri, Avinash R ^a   Aliot, Etienne M ^b   Capucci, Alessandro ^c   Connolly, Stuart J ^d   Crijns, Harry ^e   Hohnloser, Stefan H ^f   Kulakowski, Piotr ^g   Roy, Denis ^h   Radzik, David ⁱ   Kowey, Peter R ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b CHU NANCY BRABOIS   (France)

^c Ospedale Civile   (Italy)

^d University Hamilton   (Canada)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GOETHE UNIVERSITY   (Germany)

^g GROCHOWSKI HOSPITAL   (Poland)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ SANOFI   (France)

Author keywords

amiodarone; atrial fibrillation; atrial flutter; celivarone; conversion; dronedarone; maintenance

Indexed keywords

AMINOTRANSFERASE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELIVARONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIOTHYRONINE; PLACEBO; THYROTROPIN;

AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; BACKACHE; BRADYCARDIA; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUSHING; FOLLOW UP; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; INFLUENZA; INSOMNIA; LIOTHYRONINE BLOOD LEVEL; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SINUS ARREST; SINUS RHYTHM; SINUSITIS; SLEEP DISORDER; THORAX PAIN; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TORSADE DES POINTES; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BENZOFURANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860840606     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02234.x     Document Type: Article

References (22)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS,: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
2. Wyndham CR,: Atrial fibrillation: The most common arrhythmia. Tex Heart Inst J 2000; 27: 257-267.
3. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ,: Stroke associated with atrial fibrillation-Incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010; 29: 43-49.
4. Padanilam BJ, Prystowsky EN,: Atrial fibrillation: Goals of therapy and management strategies to achieve the goals. Cardiol Clin 2009; 27: 189-200.
5. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL,: Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol 2010; 33: 270-279.
6. Sanoski CA,: Clinical, economic, and quality of life impact of atrial fibrillation. J Manag Care Pharm 2009; 15 (Suppl 6b): S4-S9.
7. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B,: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920.
8. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN,: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76: 47-50.
9. Vassallo P, Trohman RG,: Prescribing amiodarone: An evidence-based review of clinical indications. JAMA 2007; 298: 1312-1322.
10. Vorperian VR, Havighurst TC, Miller S, January CT,: Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
11. Mason JW,: Amiodarone. N Engl J Med 1987; 316: 455-466.
12. (accessed 25 February 2011).
13. European Medicines Agency: Multaq (dronedarone) European Public Assessment Report. (accessed 8 June 2011).
14. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ,: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
15. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G,: Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941-946.
16. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH,: Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003; 24: 1,481-1,487.
17. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr.,: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2,385-2,390.
18. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M,: Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace 2011; 13: 329-345.
19. Kathofer S, Thomas D, Karle CA,: The novel antiarrhythmic drug dronedarone: Comparison with amiodarone. Cardiovasc Drug Rev 2005; 23: 217-230.
20. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH,: Dronedarone for the maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-999.
21. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM,: A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597-605.
22. Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D,: In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol 2005; 45: 125-135.